Ovarian Cancer: Updates in Patient Management and Treatment Selection

Mark H. Einstein, MD, MS, is once again joined by experts Stuart M. Lichtman, MD, and Jenna Z. Marcus, MD, to discuss new developments in the management of ovarian cancer. The conversation begins with an in depth discussion on the impact of COVID-19 on ovarian cancer patient care followed by a review of PARP inhibitors and a look at the role of secondary cytoreductive surgery.

COVID-19 and Ovarian Cancer Treatment

The panel discusses the impact of the COVID-19 pandemic on their practices and patient care. Included in the discussion is a review of the ASCO Special Report on Cancer Care Delivery During the COVID-19 Pandemic, which can be found here.

Up Next

COVID-19 and Ovarian Cancer Treatment
PARP Inhibitors
Shared Decision Making
Secondary Cytoreductive Surgery

In 2019, Mark H. Einstein, MD, MS, Stuart M. Lichtman, MD, and Jenna Z. Marcus, MD, discussed emerging therapeutics, surgical innovations, and treatment options for primary and advanced/recurrent ovarian cancer. To watch this roundtable, please click on the video links below.

Adjuvant Treatments
BRCA Testing/PARP Inhibitors
Surgical Innovations
Fertility Sparing
Recurrent Ovarian Cancer

About the Panel

Mark H. Einstein, MD, MS

Chair, Professor, Department of Obstetrics, Gynecology, and Reproductive Health, Rutgers New Jersey Medical School; Attending Physician, Chief of Service, Department of Obstetrics, Gynecology, and Reproductive Health, Division of Gynecologic Oncology, University Hospital, Newark, New Jersey

Stuart M. Lichtman, MD

Professor, Department of Medicine, Weill Cornell Medical College; Attending Physician, Department of Medicine, Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center, Commack, New York

Jenna Z. Marcus, MD

Assistant Professor, Department of Obstetrics, Gynecology, and Reproductive Health, Division of Gynecologic Oncology, Rutgers New Jersey Medical School, Newark, New Jersey

Disclosures

Mark H. Einstein, MD, MS, has disclosed the following relevant financial relationships: serve(d) as an unpaid advisor or participated in unpaid education speaking activities for: Merck; Hologic; Papivax; Cynvec; Altum Pharma; received research grant (paid to Rutgers University) from: Roche; Johnson and Johnson; Pfizer; AstraZeneca; Advaxis; Inovio.

Stuart M. Lichtman, MD, has disclosed no relevant financial relationships.

Jenna Z. Marcus, MD, has disclosed the following relevant financial relationships: serve(d) as an unpaid advisor for: Tesaro; have a 5% or greater equity interest in: Merck